Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Short Interest Update
by Mitch Edgeman · The Markets DailyNeuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 509,158 shares, a decline of 80.2% from the March 15th total of 2,570,623 shares. Based on an average trading volume of 32 shares, the days-to-cover ratio is currently 15,911.2 days.
Neuren Pharmaceuticals Stock Performance
NURPF stock opened at C$8.22 on Friday. Neuren Pharmaceuticals has a twelve month low of C$6.60 and a twelve month high of C$14.80. The business has a fifty day moving average of C$8.94 and a 200-day moving average of C$11.41.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.
The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.